Rather, convincing genetic evidence in CMT‐aaRS animal models has shown that a gain‐of‐toxic‐function mechanism underlies CMT‐aaRS pathogenesis, and interference with VEGF‐Nrp1 signaling is a possible molecular mechanism contributing to CMT‐GlyRS. This evidence concerns the gene GARS1 and Charcot-Marie-Tooth disease.